Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Mol Cancer Ther. 2015 Sep 2;14(11):2519–2526. doi: 10.1158/1535-7163.MCT-15-0383

Figure 1.

Figure 1

Cell viability assay of the four USC cell lines treated with neratinib, taselisib and the combination of both at the indicated concentration for 72 hrs. Cell viability was analyzed by flow cytometry and was normalized to the mean of the control group receiving no drug, so that all data were expressed as a proportion of the control. Data are expressed as mean ± SEM from three independent experiments (*=P<0.05 when compared to the control, to neratinib and to taselisib)